ASCO Adds New Combos for Metastatic Noncastrate Prostate Cancer

July 31, 2018 – Use of androgen deprivation therapy (ADT) in combination with docetaxel or abiraterone in newly diagnosed cases of metastatic noncastrate prostate cancer (mNCPC) is recommended in recently updated American Society of Clinical Oncology (ASCO) guidelines. Historically, mNCPC has been treated with ADT alone until progression; ASCO noted a survival benefit from adding docetaxel or abiraterone, based on a review of several trials … (leggi tutto)